Xention Acquires Clinical Development Compound

Xention Ltd has announced that it has acquired exclusive rights to develop certain ion channel modulators from Scion Pharmaceuticals, Inc. of Medford, MA.

The compounds were originally developed at Bristol-Myers Squibb (BMS) with whom Xention have entered into a separate agreement under which they will assume and amend the previous license agreement with Scion.

The licensed compounds may be tested to determine efficacy in a number of disorders including overactive bladder (OAB), irritable bowel syndrome and erectile dysfunction.

The most advanced compound has already been subjected to pre-clinical and Phase I clinical development and will be developed further by Xention for the treatment of OAB.

Around 50 million people worldwide suffer from OAB disorders and the market is expected to grow to US$2billion by 2008 in the US alone.

Xention Limited

Xention Limited
Atrial fibrillation drug development



DownloadFull Press Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.